— A single locally administered intra-articular injection of PCRX-201 into the knee was well tolerated in patients with moderate-to-severe knee osteoarthritis —

— Exploratory clinical outcome measures showed improvements out to two years in pain, stiffness, and function across all doses and groups —

— Phase 2 ASCEND trial of PCRX-201 in knee osteoarthritis advancing with first topline read out on track for year-end 2026 —

BRISBANE, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced the publication of positive two-year results from its Phase 1 clinical trial evaluating PCRX-201 (enekinragene inzadenovec), the company’s investigational locally administered gene therapy for knee osteoarthritis (OA). Published in the Annals of the Rheumatic Diseases, the study showed that PCRX-201, when administered as a single local administration via intra-articular injection into the knee, was well tolerated in patients with moderate to severe knee osteoarthritis. Through two years of follow-up, exploratory outcome measures showed improvements in pain, stiffness, and function across all dose cohorts among patients who remained in the study.